Analysis of APL1β28, a surrogate marker for Alzheimer Aβ42, indicates altered precision of γ-cleavage in the brains of Alzheimer disease patients

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 42-45

  Okochi, Masayasu ^a   Tagami, Shinji ^a   Takeda, Masatoshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer disease biomarker; Amyloid precursor like protein 1; Amyloid peptide 42; Cerebrospinal fluid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR LIKE PROTEIN 1BETA28; BIOLOGICAL MARKER; PEPTIDE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; APLP1 PROTEIN, HUMAN; DIAGNOSTIC AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ARTICLE; BRAIN; CEREBROSPINAL FLUID; CHEMICAL STRUCTURE; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; HUMANS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS;

EID: 76549134335     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000283481     Document Type: Conference Paper

References (18)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-4249.
2. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
3. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-648.
4. Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T: Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999; 45: 504-511.
5. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and lateonset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680.
6. Okochi M, Steiner H, Fukumori A, Tanii H, Tomita T, Tanaka T, Iwatsubo T, Kudo T, Takeda M, Haass C: Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. EMBO J 2002; 21:5408-5416.
7. Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, Jiang J, Mori K, Tatsumi S, Arai T, Ikeuchi T, Kasuga K, Tokuda T, Kondo M, Ikeda M, Deguchi K, Kazui H, Tanaka T, Morihara T, Hashimoto R, Kudo T, Steiner H, Haass C, Tsuchiya K, Akiyama H, Kuwano R, Takeda M: The 28- amino acid form of an APLP1-derived A beta-like peptide is a surrogate marker for A beta42 production in the central nervous system. EMBO Mol Med 2009;1:223-235.
8. Saido TC, Iwata N: Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 2006; 54: 235-253.
9. Jingwei J, Okochi M, Tagami S, Nishitomi K, Yanagida K, Nakayama T, Tatsimi S, Mori K, Takeda M: Macrophage colony stimulating factor is associated with excretion of amyloid-γ peptides from cerebrospinal fluid to peripheral blood. Psychogeriatrics 2008;8: 188-195.
10. Kumagai R, Matsumlya M, Tada Y, Miyakawa K, Ichimlya Y, Arai H: Long-term effect of donepezil for Alzheimer's disease: Retrospective clinical evaluation of drug efficacy in Japanese patients. Psychogeriatrics 2008; 8:19-23.
11. Tanaka T, Kazui H, Morihara T, Sadik G, Kudo T, Takeda M: Post-marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer's disease with BPSD. Psychogeriatrics 2008;8:114-123.
12. Inoue J, Hoshino R, Nojima H, Okamoto N: Investigation of the short- and long-term effects of donepezil on cognitive function in Alzheimer's disease. Pyschogeriatrics 2009; 9:27-33.
13. Nozawa M, Ichikawa Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H: Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics 2009;9:50-55.
14. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B, Walsh DM, Koo EH, Golde TE: Substrate-targeting gamma- secretase modulators. Nature 2008; 453: 925-929.
15. Golde TE, Kukar TL: Medicine. Avoiding unintended toxicity. Science 2009; 324: 603-604.
16. Okochi M, Fukumori A, Jiang J, Itoh N, Kimura R, Steiner H, Haass C, Tagami S, Takeda M: Secretion of the Notch-1 Abetalike peptide during Notch signaling. J Biol Chem 2006; 281: 7890-7898.
17. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
18. Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul S, Schafer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May PC, Karran E, Wiltfang J, D'Hooge R, De Strooper B: Gamma- Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 2009; 324: 639-642.